Companies in the consortium locate postdocs at universities and offer them funding to work on
industry projects in such areas as nanobiotechnology, marine biotechnology, and
vaccine development.
Brendan Shaw, chief executive of biotechnology
industries group Medicines Australia, welcomes the report: «It reinforces the importance of having a strong, stable IP system that allows
companies to recoup their costs and commercialize new medicines and
vaccines».